Short report of esophageal Cancer.docx
- 文档编号:2480063
- 上传时间:2022-10-30
- 格式:DOCX
- 页数:9
- 大小:126.21KB
Short report of esophageal Cancer.docx
《Short report of esophageal Cancer.docx》由会员分享,可在线阅读,更多相关《Short report of esophageal Cancer.docx(9页珍藏版)》请在冰豆网上搜索。
ShortreportofesophagealCancer
AphaseI/IItrialofpaclitaxelandoxaliplatincombinedwithradiotherapyinpatientswithlocalizedesophagealcancer
Abstract
Purpose:
Toassesstheefficacyandtoxicityofpaclitaxelandoxaliplatincombinedwithradiotherapyinpatientswithlocalizedesophagealcancer.
Methods:
Thirty-fourpatientswithlocalizedesophagealcancerweretreatedwithpaclitaxel135mg/m²andoxaliplatin75mg/m²ondays1and29ofa29-daycyclecombinedwith60Gy/30Fradiotherapy.Patientswithlocalizedesophagealcancerwereeligibleforthetrial.
Results:
Thirty-onepatients(31/34)withlocalizedesophagealcancercompletethecombined-modalitytherapywhohadthefollowingcharacteristics:
medianage66years(range39–80);Karnofskyperformancestatus≥70%.Therewere32patients(94.12%)withsquamous-cellcarcinomaoftheesophagusand1patient(2.94%)hadanadenocarcinomaand1patient(2.94%)hadanadenosqumouscarcinoma.NCIgrade4toxicity(leukopenia)wasobservedinfivepatients.Non-haematologicaltoxicityconsistedmainlyofalopeciaandgrade1/2radiationesophagitisandbronchitisandgastrointestinalreaction.Theoverallresponseratewas93.5%(29/31)with3patients(9.68%)achievingcompleteresponse.Medianoverallsurvivaltimewas14.5months(range2.4–82)andmediantimetoprogressionordistantmetastasiswas22.17months(range?
?
?
–?
?
?
).Therewerenotreatment-relateddeaths
Conclusion:
Thisregimendemonstratesefficacyandwelltoleranceoftoxicityinpatientswithlocalizedesophagealcancerandmaybeatreatmentoptionforthispopulationinanearfuture.
Keywords:
Oxaliplatin·Paclitaxel·radiotherapy·chemotherapy
localizedesophagealcancer
Introduction:
(japan)Esophagealcancerconstitutesaglobalhealthburden,withbetween400,000and500,000newcasesdiagnosedannually[1,2].Itistheeighthmostcommoncancerworldwideandrankssixthasacauseofcancerdeath[2].Theoverallincidenceofesophagealcancerappearstoberising,principallyduetoanincreaseintheincidenceofadenocarcinomaofthelowerthirdoftheesophagusinwesterncountries[3-5].Thismaybeduetoincreasingratesofobesity,gastro-esophagealreflux,andBarrett’sesophagusinthosecountries.(奥沙利铂+紫衫模板)About90%ofallpatientsdiagnosedwithesophagealcancerwilldieasaconsequenceofthisdisease.Besidesthepredominantlylatediagnosis,anotherreasonforthispoorprognosisofthistumouristhelimitedeffectivenessofsystemictherapy[6].(奥沙利铂+紫衫模板)Evenifthereisnoestablishedstandardchemoradiationtherapy,cisplatin+5-Fucombinedwithradiotherapyareacceptedasastandardofcare[7,8].Oxaliplatinisathird-generationplatinumcompoundwithafavourabletoxicityprofileascomparedtocisplatin[3,4].(china)Paclitaxel,anewbroad-spectrumcytotoxicantineoplasticisnowwidelyusedforthetreatmentofovariancancer,breastcancer,andlungcancer,andrecently,hasshownsomepromisingresponsesagainstdigestivetractcancer.MultiplePhaseI–IIstudieshavedemonstratedthatTaxaneshavesignificantactivityinpatientswithlocallyadvancedandmetastaticesophagealcancer[2,5-9].Asasingleagent,paclitaxelhasbeenshowntoachievearesponserateof32%inesophagealcancerandgastroesophagealjunctioncancer[10].
(Japan)Ilsonetal.[21]showedthatpaclitaxel80mg/m²administeredbyweekly1-hinfusionwaswelltoleratedandshowedmodestactivityinadvancedesophagealcancer.AphaseItrialinJapanstudiedweeklypaclitaxelforsolidtumors,inwhichpaclitaxelwasadministeredweeklyover1hfor6weeksfollowedbya1-weekbreak.Paclitaxeldosewasescalatedfrom80–120mg/m²withnodoselimitingtoxicityobserved.(Peripheralneuropathydevelopedinallsixpatientswhoreceived120mg/m²/weekandfourpatientsdiscontinuedtreatment[22].Adoseof120mg/m²wasthereforesetasthemaximumacceptabledose(MAD)and100mg/m²recommendedforphaseIIstudies).Wethereforeevaluatedtheefficacyandtolerabilityofpaclitaxel135mg/m²andoxaliplatin75mg/m²combinedwith60Gy/30Fradiotherapyinpatientswithlocalizedesophagealcancer.(证据不足).
PatientsandMethods
ThisphaseI/IIstudywasconductedat1stHospitalAffiliatedtoWenzhouMedicalCollege.Eligiblepatientswereadultsofatleast18yearsofage(noupperlimit)withhistologicallyconfirmedsquamouscellcarcinoma,adenocarcinomaoradenosquamouscarcinomaoftheesophagus.(RTOG9405)Karnofskyperformancestatusof70orgreater,(奥沙利铂+紫衫模板)Adequatelydefinedhematological,renal,andhepaticfunctionwererequired[hemoglobin≥90g/L,neutrophils≥1.5×109/L,plateletscount≥100×109/L,creatinine≤1.5timesupperlimitofnormalvalue(ULN),totalserumbilirubinlevl≤1.5ULNandalanineaminotransferase(ALT)≤2.5ULN],bronchoscopytoexcludeatracheoesophagealfistulaifthelesionwaslessthan30cmfromtheincisors,chest
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- Short report of esophageal Cancer